|Bid||3.2800 x 3200|
|Ask||3.3200 x 2200|
|Day's Range||3.0700 - 3.7200|
|52 Week Range||0.2950 - 3.7200|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Top Ranked Momentum Stocks to Buy for July 10th
As of late, it has definitely been a great time to be an investor in Unum Therapeutics Inc. (UMRX).
Unum Therapeutics (UMRX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]
Unum Therapeutics Inc (UMRX) delivered earnings and revenue surprises of 39.39% and 134.37%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Unum Therapeutics Inc. (NASDAQ:UMRX) shareholders will doubtless be very grateful to see the share price up 53% in the...
Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved dearly, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 20 S&P 500 […]
Unum Therapeutics Inc. (UMRX) delivered earnings and revenue surprises of -25.81% and -76.87%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Unum Therapeutics Inc. (UMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Unum Therapeutics Inc. (UMRX) delivered earnings and revenue surprises of 12.82% and 1.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Biotech stocks came under pressure this week along with the broader market amid an earnings spate. The biggest news break was an FDA probe into data integrity issues with Novartis AG (NYSE: NVS )'s regulatory ...
As every investor would know, you don't hit a homerun every time you swing. But serious investors should think long...